Silexion

Silexion is a clinical-stage, oncology-focused biotechnology company dedicated to developing innovative therapies for solid tumor cancers with poor treatment outcomes due to KRAS oncogene mutations. The company conducted a Phase 2a clinical trial, demonstrating significant efficacy compared to chemotherapy alone. Silexion is committed to advancing cancer treatment and further developing a second-generation product for locally advanced pancreatic cancer.